Trafficking dynamics of PCSK9-induced LDLR degradation: Focus on human PCSK9 mutations and C-terminal domain

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Poirier, Steve ^a,b   Hamouda, Hocine Ait ^a,b   Villeneuve, Louis ^a   Demers, Annie ^a   Mayer, Gaétan ^a,b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; ENHANCED GREEN FLUORESCENT PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PCSK9 PROTEIN; UNCLASSIFIED DRUG; LDLR PROTEIN, HUMAN; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

ARTICLE; BINDING AFFINITY; BINDING SITE; BIOACCUMULATION; CARBOXY TERMINAL SEQUENCE; CELL ASSAY; CELL MIGRATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DUAL FLUORESCENCE CELL BASED ASSAY; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; GAIN OF FUNCTION MUTATION; GENE; GENE LOCATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; LOSS OF FUNCTION MUTATION; MOLECULAR DYNAMICS; MOLECULAR IMAGING; PCSK9 GENE; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TRANS GOLGI NETWORK; ANTAGONISTS AND INHIBITORS; GENETICS; HEP-G2 CELL LINE; METABOLISM; MUTATION; PROTEIN TRANSPORT;

HEP G2 CELLS; HUMANS; MUTATION; PROPROTEIN CONVERTASE 9; PROTEIN DOMAINS; PROTEIN TRANSPORT; PROTEOLYSIS; RECEPTORS, LDL;

EID: 84975485811     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157230     Document Type: Article

References (61)

1. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007; 116(16):1832-1844. PMID: 17938300
2. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013; 34(45):3478-3490a. doi: 10.1093/eurheartj/eht273 PMID: 23956253
3. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003; 100(3):928-933. PMID: 12552133
4. Maxwell KN, Breslow JL. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A. 2004; 101(18):7100-7105. PMID: 15118091
5. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003; 34(2):154-156. PMID: 12730697
6. Cohen JC, Boerwinkle E, Mosley TH Jr., Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006; 354(12):1264-1272. PMID: 16554528
7. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372(16):1500-1509. doi: 10.1056/NEJMoa1500858 PMID: 25773607
8. Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2004; 24(8):1454-1459. PMID: 15178557
9. Horton JD, Shah NA, Warrington JA, Anderson NN, Park SW, Brown MS, et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci U S A. 2003; 100(21):12027-12032. PMID: 14512514
10. Li H, Dong B, Park SW, Lee HS, Chen W, Liu J. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem. 2009; 284(42):28885-28895. doi: 10.1074/jbc.M109.052407 PMID: 19687008
11. Cunningham D, Danley DE, Geoghegan KF, Griffor MC, Hawkins JL, Subashi TA, et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol. 2007; 14(5):413-419. PMID: 17435765
12. Naureckiene S, Ma L, Sreekumar K, Purandare U, Lo CF, Huang Y, et al. Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch Biochem Biophys. 2003; 420(1):55-67. PMID: 14622975
13. Piper DE, Jackson S, Liu Q, Romanow WG, Shetterly S, Thibault ST, et al. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure. 2007; 15(5):545-552. PMID: 17502100
14. Chen XW, Wang H, Bajaj K, Zhang P, Meng ZX, Ma D, et al. SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion. Elife. 2013; 2:e00444. doi: 10.7554/eLife.00444 PMID: 23580231
15. Poirier S, Mamarbachi M, Chen WT, Lee AS, Mayer G. GRP94 Regulates Circulating Cholesterol Levels through Blockade of PCSK9-Induced LDLR Degradation. Cell Rep. 2015; 13(10):2064-2071. doi: 10.1016/j.celrep.2015.11.006 PMID: 26628375
16. Butkinaree C, Canuel M, Essalmani R, Poirier S, Benjannet S, Asselin MC, et al. Amyloid Precursorlike Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other. J Biol Chem. 2015; 290(30):18609-18620. doi: 10.1074/jbc.M115.647180 PMID: 26085104
17. Gustafsen C, Kjolby M, Nyegaard M, Mattheisen M, Lundhede J, Buttenschon H, et al. The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion. Cell Metab. 2014; 19(2):310-318. doi: 10.1016/j.cmet.2013.12.006 PMID: 24506872
18. DeVay RM, Shelton DL, Liang H. Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2). J Biol Chem. 2013; 288(15):10805-10818. doi: 10.1074/jbc.M113.453373 PMID: 23430252
19. Poirier S, Mayer G, Poupon V, McPherson PS, Desjardins R, Ly K, et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem. 2009; 284(42):28856-28864. doi: 10.1074/jbc.M109.037085 PMID: 19635789
20. Holla OL, Cameron J, Berge KE, Ranheim T, Leren TP. Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly. BMC Cell Biol. 2007; 8:9. PMID: 17328821
21. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest. 2006; 116(11):2995-3005. PMID: 17080197
22. Nassoury N, Blasiole DA, Tebon Oler A, Benjannet S, Hamelin J, Poupon V, et al. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic. 2007; 8(6):718-732. PMID: 17461796
23. Poirier S, Mayer G. The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des Devel Ther. 2013; 7:1135-1148. doi: 10.2147/DDDT.S36984 PMID: 24115837
24. Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007; 282(25):18602-18612. PMID: 17452316
25. Kwon HJ, Lagace TA, McNutt MC, Horton JD, Deisenhofer J. Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci U S A. 2008; 105(6):1820-1825. doi: 10.1073/pnas.0712064105 PMID: 18250299
26. Fisher TS, Lo Surdo P, Pandit S, Mattu M, Santoro JC, Wisniewski D, et al. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J Biol Chem. 2007; 282(28):20502-20512. PMID: 17493938
27. Lambert G, Charlton F, Rye KA, Piper DE. Molecular basis of PCSK9 function. Atherosclerosis. 2009; 203(1):1-7. doi: 10.1016/j.atherosclerosis.2008.06.010 PMID: 18649882
28. Timms KM, Wagner S, Samuels ME, Forbey K, Goldfine H, Jammulapati S, et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet. 2004; 114(4):349-353. PMID: 14727179
29. Benjannet S, Saavedra YG, Hamelin J, Asselin MC, Essalmani R, Pasquato A, et al. Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events. J Biol Chem. 2010; 285(52):40965-40978. doi: 10.1074/jbc.M110.154815 PMID: 20937814
30. Lo Surdo P, Bottomley MJ, Calzetta A, Settembre EC, Cirillo A, Pandit S, et al. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. EMBO Rep. 2011; 12(12):1300-1305. doi: 10.1038/embor.2011.205 PMID: 22081141
31. Abifadel M, Guerin M, Benjannet S, Rabes JP, Le Goff W, Julia Z, et al. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia. Atherosclerosis. 2012; 223(2):394-400. doi: 10.1016/j.atherosclerosis.2012.04.006 PMID: 22683120
32. McNutt MC, Lagace TA, Horton JD. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem. 2007; 282(29):20799-20803. PMID: 17537735
33. Zhang DW, Garuti R, Tang WJ, Cohen JC, Hobbs HH. Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci U S A. 2008; 105(35):13045-13050. doi: 10.1073/pnas.0806312105 PMID: 18753623
34. Yamamoto T, Lu C, Ryan RO. A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor. J Biol Chem. 2011; 286(7):5464-5470. doi: 10.1074/jbc.M110.199042 PMID: 21149300
35. Tveten K, Strom TB, Berge KE, Leren TP. PCSK9-mediated degradation of the LDL receptor generates a 17 kDa C-terminal LDL receptor fragment. J Lipid Res. 2013; 54(6):1560-1566. doi: 10.1194/jlr.M034371 PMID: 23509406
36. Seidah NG, Awan Z, Chretien M, Mbikay M. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014; 114(6):1022-1036. doi: 10.1161/CIRCRESAHA.114.301621 PMID: 24625727
37. Mayer G, Poirier S, Seidah NG. Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J Biol Chem. 2008; 283(46):31791-31801. doi: 10.1074/jbc.M805971200 PMID: 18799458
38. Seidah NG, Poirier S, Denis M, Parker R, Miao B, Mapelli C, et al. Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. PLoS One. 2012; 7(7):e41865. doi: 10.1371/journal.pone.0041865 PMID: 22848640
39. Ni YG, Condra JH, Orsatti L, Shen X, Di Marco S, Pandit S, et al. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J Biol Chem. 2010; 285(17):12882-12891. doi: 10.1074/jbc.M110.113035 PMID: 20172854
40. Demers A, Samami S, Lauzier B, Des Rosiers C, Sock ET, Ong H, et al. PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver. Arterioscler Thromb Vasc Biol. 2015; 35(12):2517-2525. doi: 10.1161/ATVBAHA.115.306032 PMID: 26494228
41. Poirier S, Samami S, Mamarbachi M, Demers A, Chang TY, Vance DE, et al. The Epigenetic Drug 5-Azacytidine Interferes with Cholesterol and Lipid Metabolism. J Biol Chem. 2014; 289(27):18736-18751. doi: 10.1074/jbc.M114.563650 PMID: 24855646
42. Saraste J, Palade GE, Farquhar MG. Temperature-sensitive steps in the transport of secretory proteins through the Golgi complex in exocrine pancreatic cells. Proc Natl Acad Sci U S A. 1986; 83(17):6425-6429. PMID: 3462704
43. Rapsomaniki MA, Kotsantis P, Symeonidou IE, Giakoumakis NN, Taraviras S, Lygerou Z. easyFRAP: an interactive, easy-to-use tool for qualitative and quantitative analysis of FRAP data. Bioinformatics. 2012; 28(13):1800-1801. doi: 10.1093/bioinformatics/bts241 PMID: 22543368
44. Lippincott-Schwartz J, Snapp E, Kenworthy A. Studying protein dynamics in living cells. Nat Rev Mol Cell Biol. 2001; 2(6):444-456. PMID: 11389468
45. Bendayan M. Colloidal gold post-embedding immunocytochemistry. Prog Histochem Cytochem. 1995; 29(4):1-159. PMID: 7480783
46. Tsien RY. Constructing and exploiting the fluorescent protein paintbox (Nobel Lecture). Angew Chem Int Ed Engl. 2009; 48(31):5612-5626. doi: 10.1002/anie.200901916 PMID: 19565590
47. Shu X, Shaner NC, Yarbrough CA, Tsien RY, Remington SJ. Novel chromophores and buried charges control color in mFruits. Biochemistry. 2006; 45(32):9639-9647. PMID: 16893165
48. Mayne J, Dewpura T, Raymond A, Bernier L, Cousins M, Ooi TC, et al. Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture. Clin Chem. 2011; 57(10):1415-1423. doi: 10.1373/clinchem.2011.165191 PMID: 21813713
49. Holla OL, Cameron J, Tveten K, Strom TB, Berge KE, Laerdahl JK, et al. Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors. J Lipid Res. 2011; 52(10):1787-1794. doi: 10.1194/jlr.M018093 PMID: 21771976
50. Bottomley MJ, Cirillo A, Orsatti L, Ruggeri L, Fisher TS, Santoro JC, et al. Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants. J Biol Chem. 2009; 284(2):1313-1323. doi: 10.1074/jbc.M808363200 PMID: 19001363
51. Nguyen MA, Kosenko T, Lagace TA. Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts. J Lipid Res. 2014; 55(2):266-275. doi: 10.1194/jlr.M044156 PMID: 24296664
52. McNutt MC, Kwon HJ, Chen C, Chen JR, Horton JD, Lagace TA. Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem. 2009; 284(16):10561-10570. doi: 10.1074/jbc.M808802200 PMID: 19224862
53. Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W, et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem. 2004; 279(47):48865-48875. PMID: 15358785
54. Cameron J, Holla OL, Ranheim T, Kulseth MA, Berge KE, Leren TP. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum Mol Genet. 2006; 15(9):1551-1558. PMID: 16571601
55. Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem. 2008; 283(4):2363-2372. PMID: 18039658
56. Bergeron N, Phan BA, Ding Y, Fong A, Krauss RM. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: A New Therapeutic Mechanism for Reducing Cardiovascular Disease Risk. Circulation. 2015; 132(17):1648-1666. doi: 10.1161/CIRCULATIONAHA.115.016080 PMID: 26503748
57. Brown MS, Goldstein JL. Receptor-mediated endocytosis: insights from the lipoprotein receptor system. Proc Natl Acad Sci U S A. 1979; 76(7):3330-3337. PMID: 226968
58. Bevis BJ, Glick BS. Rapidly maturing variants of the Discosoma red fluorescent protein (DsRed). Nat Biotechnol. 2002; 20(1):83-87. PMID: 11753367
59. Saavedra YG, Day R, Seidah NG. The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway. J Biol Chem. 2012; 287(52):43492-43501. doi: 10.1074/jbc.M112.394023 PMID: 23105118
60. Kotowski IK, Pertsemlidis A, Luke A, Cooper RS, Vega GL, Cohen JC, et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet. 2006; 78(3):410-422. PMID: 16465619
61. Dewpura T, Raymond A, Hamelin J, Seidah NG, Mbikay M, Chretien M, et al. PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and circulates as a phosphoprotein in humans. FEBS J. 2008; 275(13):3480-3493. doi: 10.1111/j.1742-4658.2008.06495.x PMID: 18498363